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Background: Both the T cell immunoglobulin domain- and mucin domain-containing molecule-3 (Tim-3) and the death
receptor Fas contribute to the pathogenesis of various autoimmune diseases, including systemic lupus erythematosus
(SLE). The aim of the present study was to determine whether Tim-3 and Fas are co-expressed on certain peripheral T
lymphocyte subsets, and whether this expression is associated with greater disease activity in SLE.
Methods: Peripheral blood mononuclear cells were isolated from 46 patients newly diagnosed with SLE and 28 age- and
sex-matched healthy controls (HCs). Expression of Tim-3 and Fas on T subsets was analyzed by flow cytometry,
while mRNA levels of the Tim-3 ligand galectin-9 and Fas ligand FasL were assayed using real-time RT-PCR.
Results: The proportions of CD3+CD4+ and CD3+CD4- T cells expressing Tim-3+ and Tim+Fas+ were significantly
higher in patients than in HCs (p < 0.05), while the proportions of these subtypes expressing Fas were similar for
the two groups. Patients with active SLE, as defined by their score on the SLE Disease Activity Index, had lower
proportions of CD3+CD4+ T cells and higher proportions of CD3+CD4+Tim-3+ and CD3+CD4+Tim-3+Fas+ T cells
than did patients with stable SLE. Serum levels of complement C3 and C4 proteins, considered as a marker of SLE
activity, correlated negatively with proportions of CD3+CD4+ and CD3+CD4- T cells expressing Tim-3.
Conclusions: Expression of Tim-3 and co-expression of Tim-3 and Fas on certain peripheral T subsets are associated
with disease activity in SLE patients. Future research should examine whether the same is true of other T subsets
implicated in SLE, and should explore the potential role(s) of Tim-3 in the disease pathway.
Virtual slides: http://www.diagnosticpathology.diagnomx.eu/vs/1855527845145188
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Systemic lupus erythematosus (SLE) has been extensively
studied as a disease of adaptive immunity. T cell dysfunc-
tion, cytokine production [1–4] and dysregulation of cell
apoptosis [5, 6] are known to play pivotal roles in SLE,
but how the disease begins and progresses is unclear.
Signaling mediated by the Fas receptor and its natural
ligand, FasL, contribute to the pathogenesis of SLE [5–8].
Such signaling contributes to the pathogenesis of various* Correspondence: drshuqiang@163.com
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creativecommons.org/publicdomain/zero/1.0/autoimmune diseases by promoting apoptosis and im-
mune escape [9]. Fas promotes the removal of activated T
cells via activation-induced cell death, while FasL, a mem-
ber of the tumor necrosis factor super family, initiates the
death signaling cascade and promotes apoptosis [10]. Per-
ipheral blood T lymphocytes show higher apoptosis rates
in patients with SLE than healthy controls (HCs), and this
correlates with greater mRNA levels of Fas [11, 12] and
FasL [13, 14].
T cell immunoglobulin domain- and mucin domain-
containing molecule-3 (Tim-3), a member of the Tims
family, has been implicated in the pathogenesis of
asthma, type 1 diabetes, collagen-induced arthritis and
other autoimmune diseases [15–19]. Whether it alsoicle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
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marily on the surface of activated Th1 cells, and it binds
to its ligand galectin-9 to negatively regulate interferon-γ
(IFN-γ) secretion [20, 21]. Other immune cells can also
express Tim-3,such as cytotoxic T lymphocytes (Tcl),
Th17, macrophages, dendritic cells and natural killer T
cells; such expression affects immune functions in mice
and humans [22, 23]. Tim-3 functions as the phagocytic
receptor to remove apoptotic cells [24], while binding of
galectin-9 to the carbohydrate chains of Tim-3 has been
shown to induce Th1 cell death in vitro [21].
Previous work from our laboratory showed that per-
ipheral blood mononuclear cells (PBMCs) from patients
with SLE express similar levels of Tim-3 mRNA as
PBMCs from HCs [25]. However, whether Tim-3 expres-
sion is similar across the various subsets of PBMCs, in-
cluding T lymphocytes, B lymphocytes and monocytes,
is unclear. In addition, since both Tim-3 and Fas are
apoptosis-associated surface molecules, it would be im-
portant to investigate whether the expression of one cor-
relates with expression of the other on peripheral T
subsets in patients with SLE relative to HCs. Such stud-
ies may help provide insights into SLE pathogenesis.
Therefore, in the present study, we quantified the propor-
tions of the two main peripheral T subsets cells expressing
Fas and/or Tim-3 in patients with SLE and HCs. We also
examined mRNA expression of the corresponding receptor
ligands galectin-9 and FasL in PBMCs. Finally, we exam-
ined possible relationships of Tim-3/Galectin-9 and Fas/
FasL expression with SLE disease activity.
Methods
Patients and HCs
A total of 46 patients newly diagnosed with SLE accord-
ing to revised criteria from the American College of
Rheumatology for the classification of systemic lupus er-
ythematosus [26] were included in the study. Patients
were admitted to our hospital from June 2009 to March
2010. Clinical disease activity was assessed at the time of
measurement according to the systemic lupus erythema-
tosus disease activity index (SLEDAI) 2000. Patients with
a SLEDAI score ≥ 10 were defined as having active SLE
[27], while patients with lower SLEDAI scores were de-
fined as having stable disease. As a reference group, 28
age- and sex-matched HCs were enrolled. The study
was approved by the Institutional Review Board of Qilu
Hospital of Shandong University. All patients and HCs
gave informed consent for participation in the study.
Flow cytometry
Fresh PBMCs were collected from patients with SLE and
HCs and prepared for fluorescence-activated cell sorting
(FACS). The cell surface was stained using the following
fluorochrome-conjugated monoclonal antibodies: anti-CD3 PE-Cy5, anti-CD4 FITC, anti-Fas-APC (mouse IgG1,
BD Biosciences, USA) and anti-Tim-3 PE (rat IgG2A,
R&D, USA). Cells were then fixed and permeabilized with
RBC lysis buffer (BD Biosciences). Gates and quadrants
were set based on isotype control staining (BD Biosciences
and R&D). Data were acquired using multicolor analysis
on the FACS Calibur flow cytometer (BD Biosciences) and
analyzed by FlowJo software 7.6.2 (Tree Star, Ashland,
OR, USA).
Real-time quantitative reverse transcription-PCR to measure
galectin-9 and FasL mRNA levels
PBMCs were isolated from peripheral blood using dens-
ity gradient centrifugation based on Ficoll (Haoyang
Biosciences, Tianjin, China). Total cellular RNA was ex-
tracted using Trizol reagent (TransGen Biosciences,
Beijing, China). Reverse transcription was performed
using the TransScript First-Strand cDNA Synthesis Super-
Mix kit (TransGen Biosciences). Then amplification was
performed using an AB 7500 Real-Time PCR System (AB
Biosciences, CA, USA) following the manufacturer’s in-
structions. The Power SYBR Green PCR Master Mix kit
(AB Biosciences) was used with the following two-step
PCR protocol: 95 °C for 10 min, followed by 40 cycles of
95 °C for 15s and 60 °C for 1 min.
The following primers were used for galectin-9: forward,
5′-ACTTTCAGAACAGCTTCAATGGA-3′; reverse, 5′-
AGTCCATCATGATATCAGGCAAT-3′. The following
primers were used for FasL: forward, 5′-CAATGAAAAT
GAACACATTG-3′; reverse, 5′CCCACTTTAGAAATTA
GATC-3′. As an internal control, β-actin mRNA was amp-
lified using the following primers: forward, 5′-TTGCCGA-
CAGGATGCAGAA-3′; reverse, 5′-GCCGATCCACACG
GAGTACT-3′. Analysis of PCR products on 5 % agarose
showed the expected sizes. All reactions were run in paral-
lel in the absence of reverse transcriptase to exclude the
possibility of genomic contamination.
Serology
Serum levels of complement 3 (C3) and serum comple-
ment 4 (C4), the presence of dsDNA and anti-nuclear
antibodies (ANA), and the total number of white blood
cells (WBCs) were assayed in the clinical laboratory of
Qilu Hospital. SLEDAI scores were recorded at the time
of follow-up for SLE patients.
Statistical analysis
All values are expressed as mean ± SD unless stated
otherwise. Inter-group differences were assessed for sig-
nificance using the Mann-Whitney U-test. Spearman’s
rank correlation was used to examine possible correla-
tions between patient variables and presence or activity
of SLE. The threshold for significance was defined as
Table 2 Demographic and clinical data for Chinese patients
with active or stable SLE
Active SLE Stable SLE
N 21 25
Age, yr 33.5 ± 14.2** 36.2 ± 12.3
Female, n (%) 19 (90.5)** 23 (92.0)
Male, n (%) 2 (9.5)** 2 (8.0)
ANA (+), n (%) 21 (100) 25 (100)
dsDNA (+), n (%) 14(67)* 6(24)
C3, g/L 0.64 ± 0.41* 0.94 ± 0.35
C4, g/L 0.13 ± 0.11** 0.20 ± 0.13
SLEDAI score 13.9 ± 3.2* 5.4 ± 2.1
Values shown are mean ± SD unless otherwise noted
ANA, anti-nuclear antibody; C, complement; SLEDAI, systemic lupus erythematosus
disease activity index
*p < 0.05 compared to stable SLE group
**p > 0.05 compared to stable SLE group
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Results
Demographic and clinical characteristics in patients with
SLE and HCs
Patients and HCs showed no significant differences in age
or sex distribution (Table 1). All patients were positive for
ANA, whereas all HCs were negative; hypocomplemente-
mia was present in 65.2 % of patients. The average number
of total WBCs in circulation was lower in patients than in
HCs (5.15 ± 2.91 vs. 5.88 ± 1.34 cells/nl), though the differ-
ence did not achieve significance (p = 0.152). The propor-
tion of lymphocytes in WBCs was significantly lower in
patients (15.54 ± 10.93 vs. 21.26 ± 5.86, p = 0.005).
Among patients, 21 (45.6 %) were classified as having
active SLE based on an SLEDAI score ≥ 10. Dividing the
patients into groups with active or stable disease re-
vealed no significant differences in age or sex distribu-
tion (Table 2). The two groups did differ significantly in
SLEDAI score, incidence of dsDNA positivity and serum
levels of C3 and C4 (p = 0.005).
CD3+CD4+T lymphocyte subsets in patients with SLE and
HCs
Patients showed a significantly lower proportion of cir-
culating CD3+CD4+ T cells than HCs did (21.96 ±
9.11vs.30.58 ± 7.75, p < 0.001; Table 1), where as the pro-
portion of CD3+CD4- T cells was similar between theTable 1 Clinical characteristics and proportions of lymphocyte




Age, yr 34.6 ± 12.7 34.8 ± 13.6
Female, n (%) 42 (91.3) 25 (89.3)
Male, n (%) 4 (8.7) 3 (10.7)
ANA (+), n (%) 46 (100) 0
C3, g/L 0.76 ± 0.36 -
C4, g/L 0.16 ± 0.12 -
SLEDAI score 8.6 ± 4.3 -
WBCs (×109/L) 5.15 ± 2.91 5.88 ± 1.34
Lymphocytes, %a 15.54 ± 10.93* 21.26 ± 5.86
CD3+CD4+ T subset, %b 21.96 ± 9.11* 30.58 ± 7.75
CD3+CD4- T subset, %b 26.28 ± 11.81 24.27 ± 7.99
Ratio of CD3+CD4+/CD3+CD4- T 0.97 ± 0.50* 1.38 ± 0.54
Values shown are mean ± SD, unless otherwise noted
ANA, anti-nuclear antibody; C, complement; SLEDAI, systemic lupus erythematosus
disease activity index; WBCs, white blood cells
aPercentage of total white blood cells in peripheral blood
bPercentage of total lymphocytes in peripheral blood
*p < 0.05 compared to healthy control grouptwo groups. As a result, the ratio of CD3+CD4+ cells to
CD3+CD4- T cells was significantly lower in patients
(0.97 ± 0.50 vs. 1.38 ± 0.54, p = 0.002).
Tim-3 expression on T cell subsets in patients and HCs
Populations of lymphocytes, CD3+CD4+ T cells and CD3
+CD4- T cells in patients and HCs were gated using
FACS (Fig. 1), and then the surface expression of Tim-3
and Fas on these subsets was assessed. Surface expres-
sion of Tim-3+, Tim-3+Fas- and Tim-3+Fas+ was signifi-
cantly higher on CD3+CD4+ T cells and CD3+CD4- T
cells in patients than on the corresponding cells in HCs
(p < 0.001; Fig. 2a-c and Fig. 3a-c). In contrast, surface ex-
pression of Fas+ and Tim-3-Fas+ was similar on CD3+CD4+
T cells and CD3+CD4- T cells in the two groups (Fig. 2d
and Fig. 3d).
Correlation of FasL and galectin-9 mRNA levels with Fas
and Tim-3 expression in CD3+T cells
Expression of the Tim-3 ligand galectin-9 mRNA in
PBMCs did not significantly correlate with Tim-3 sur-
face expression on CD3+CD4+ or CD3+CD4- T cells.
Similar results were obtained for FasL mRNA levels and
Fas expression (data not shown).
Correlation between Tim-3 expression and SLE disease
activity
Both SLEDAI and serum levels of complement proteins
can reflect SLE disease activity, and SLEDAI score in
our patients correlated negatively with serum levels of
C3 (r = -0.448, p < 0.01) and C4 (r = -0.374, p < 0.05;
Table 3). Serum levels of C3 and C4, in turn, correlated
negatively with Tim-3 surface expression (r = -0.549, p <
0.01; r = -0.453, p < 0.01) and with Tim-3+Fas+ surface
Fig. 1 Fluorescence-activated cell sorting to quantify lymphocyte subsets from patients with SLE and healthy controls (HCs). Peripheral blood
mononuclear cells from HC (left panels) and patients (right panels) were sorted to reveal proportions of (a) lymphocytes in the total cell
population, (b) CD3+CD4+ and CD3+CD4- T subsets among all lymphocytes, (c) Tim+ and Fas+ subsets among CD3+CD4+ lymphocytes and (d)
Tim+ and Fas+ subsets among CD3+CD4- lymphocytes
Song et al. Diagnostic Pathology  (2015) 10:71 Page 4 of 9co-expression(r = -0.488, p < 0.01; r = -0.476, p < 0.01) on
CD3+CD4+ T cells. Similarly, C3 and C4 levels negatively
correlated with Tim-3+ expression (r = -0.513, p < 0.01;
r = -0.416, p < 0.01) and Tim-3+Fas+ expression (r = -0.441,
p < 0.01; r = -0.495, p < 0.01) on CD3+CD4- T cells.
No correlation was found between surface Fas expres-
sion and SLEDAI score for any of the T subsetsexamined. Similarly, no correlation was found between
FasL or Galectin-9 mRNA levels and SLEDAI score.
Comparison of T cell subsets between patients with
active or stable SLE showed that patients with active dis-
ease had significantly lower proportions of CD3+CD4+ T
subsets and higher proportions of CD3+CD4+Tim-3+
and CD3+CD4+Tim-3+Fas+ cells (p = 0.01; Fig. 4).
Fig. 2 Tim-3 and Fas expression on CD3+CD4+ T cells in patients with SLE and healthy controls (HCs). CD3+CD4+ T cells from patients expressed
significantly higher levels of (a) Tim-3+, (b) Tim-3+Fas+, and (c) Tim-3+Fas-. d Fas expression on CD3+CD4+ T cells was similar between patients
and HCs. Horizontal bars indicate mean levels. &, p < 0.05; #, p > 0.05
Fig. 3 Tim-3 and Fas expression on CD3+CD4-T cells in patients with SLE and healthy controls (HCs). CD3+CD4-T cells from patients expressed
significantly higher levels of (a) Tim-3+, (b) Tim-3+Fas+, and (c) Tim-3+Fas-. d Fas expression on CD3+CD4- T cells was similar between patients and
HCs. Horizontal bars indicate mean levels. &, p < 0.05; #, p > 0.05
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Table 3 Correlations between proportions of different T cell
subsets and disease activity index in Chinese patients with SLE
SLEDAI score C3 C4
CD3+CD4+ T cells -0.075 0.108 0.182
Fas+ 0.213 0.076 0.022
Tim-3+Fas+ 0.143 -0.488b -0.476b
Tim-3+ 0.178 -0.549b -0.453b
CD3+CD4- T cells 0.205 -0.125 0.124
Fas+ -0.025 0.084 -0.035
Tim-3+Fas+ 0.112 -0.441b -0.495b
Tim-3+ 0.156 -0.513b -0.416b





aCorrelation significant at the 0.05 level (2-tailed)
bCorrelation significant at the 0.01 level (2-tailed)
Fig. 4 Comparison of proportions of different T cell subsets between patie
SLEDAI score as having active disease (score≥ 10) or stable disease (score≤
lymphocytes in patients with active disease than in those with stable disea
a larger proportion of lymphocytes in patients with active disease (&, p < 0
similar between patients with active or stable SLE (#, p > 0.05)
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In this case-control study, we compared the expression
of Tim-3+, Tim-3+Fas-, Tim-3+Fas+, Tim-3-Fas+ and Fas+
on CD3+CD4+ T cells and CD3+CD4-T cells between pa-
tients with SLE and matched HCs. We found that expres-
sion of Tim-3+, Tim-3+Fas- and Tim-3+Fas+ on CD3+CD4+
T cells and CD3+CD4- T cells was significantly higher in
patients. We did not, however, find significant correlations
between FasL mRNA expression in PBMCs and Fas+ ex-
pression on CD3+CD4+orCD3+CD4- T cells in patients; the
same was observed for galectin-9 and Tim-3. We further
found that SLEDAI score negatively correlated with serum
levels of C3 and C4. These serum levels, in turn, correlated
negatively with Tim-3+ and Tim-3+Fas+ expression on
CD3+CD4+ and CD3+CD4- T cells.
CD4+T cell subsets include Th1, Th2, Th17 and regula-
tory T cells (Treg), while CD8+ T cells are usually cyto-
toxic T cells. The CD3+CD4- T cells in our study were
mainly CD8+ T cells. Our study found a lower proportionnts with active or stable SLE. SLE patients were classified based on
9). a The CD3+CD4+ T subset made up a smaller proportion of
se, while CD3+CD4+Tim-3+ and CD3+CD4+Tim-3+Fas- subsets made up
.05). b Proportions of CD3+CD4- T cells expressing Tim and Fas were
Song et al. Diagnostic Pathology  (2015) 10:71 Page 7 of 9of CD3+CD4+ T cells and higher proportion of CD3+CD4-
T cells in patients than in HCs, leading to an abnormal ra-
tio of CD3+CD4+ T cells to CD3+CD4- T cells. This is in
accord with previous studies [28, 29], and it supports the
observations that SLE involves an imbalance of Th1⁄Th2
[30] and that abnormal expression of key signaling mole-
cules on T lymphocytes plays an important role in SLE
pathogenesis [31, 32].
Indeed, abnormal T cell signaling is thought to con-
tribute to SLE by altering gene transcription and cyto-
kine production [31–33]. One of the affected pathways
is apoptosis [5, 34]. Fas is an apoptosis-promoting cell
surface receptor, and interactions between Fas and FasL
play an essential role in maintaining immune homeosta-
sis [35]. Fas expression on total peripheral blood lym-
phocytes has been reported to be higher in SLE patients
than in HCs [11, 36, 37] and to correlate with both dis-
ease activity [11, 36]and organ damage [37]. Similarly,
Amasaki et al. reported higher mean fluorescence intensity
due to Fas expression on both CD4+ and CD8+ T cell sub-
sets in patients than in HCs [38]. In the present study,
however, Fas+Tim-3+ expression on CD3+CD4+ and
CD3+CD4- T cells was higher in patients than in HCs,
but the difference was not significant. This discrepancy
may reflect the difference between using percentage of
fluorescent cells or mean fluorescence intensity as the
outcome measure.
Increased Fas expression on lymphocytes because of
lymphocyte activation may account for the increased
susceptibility to Fas-mediated apoptosis in SLE. Induc-
tion of the T cell response can activate T cells or induce
them to express Fas and FasL. Fas+ or FasL+ T lympho-
cytes can kill each other or commit suicide directly, and
they can effect killing through autocrine and paracrine
mechanisms [39]. Fas participates in removing reactive
lymph cell clones and activated T cells from the circula-
tion. Dysregulation or inhibition of Fas-mediated signal-
ing leads to the accumulation of activated T cells, which
can cause autoimmune diseases such as SLE.
While Fas/FasL is the main pathway for cell death in
SLE pathogenesis, signaling by Tim-3/galectin-9 also con-
tributes to lymphocyte apoptosis. Tim-3 is a powerful im-
munosuppressive molecule involved in immune tolerance
and autoimmune responses. Tim-3 was initially identified
on terminally differentiated Th1 cells and negatively regu-
lates the T cell response by inducing T cell apoptosis [40].
Dysregulation of Tim-3 expression on CD4+ T cells and
CD8+ T cells is closely related to autoimmune diseases
[22, 41]. In the present study, Tim-3 expression on both
CD3+CD4+ T cells and CD3+CD4- T cells was significantly
higher in patients than in HCs. In addition, Tim-3 expres-
sion on CD3+CD4+ T cells was higher in active SLE pa-
tients than in stable SLE ones. These findings contrast
with previous work from our group showing no significantdifference in Tim-3 expression on total PBMCs between
patients and HCs [25]. This discrepancy may reflect the
different expression of Tim-3 on various PBMC subsets
other than CD3+CD4+and CD3+CD4- T cells, including
activated Th17 cells, macrophages/monocytes, dendritic
cells, and natural killer cells. Future work should clarify
what happens with Tim-3 expression in different PBMC
subsets.
Our results show that Tim-3 expression on CD3+CD4+
and CD3+CD4- T cells negatively correlated with serum
levels of C3 and C4, which correlated in turn with SLEDAI
score. As we know, C3 and C4 levels are SLE disease activity
biomarkers. Thus, the positive correlations between C3
or C4 and Tim-3 expression on T cells, especially the
CD3+CD4+ T subset suggest that Tim-3 expression
maybe can reflect SLE disease activity as well as C3 and
C4 levels. Since increased Tim-3 expression can negatively
regulate Th1 cell responses and decrease inflammation-
induced organ damage, the higher expression in patients
with SLE may reflect in part a compensatory response to
the inflammation in SLE. Future studies should examine
whether the observed higher Tim-3 expression in patients
with SLE helps drive SLE pathogenesis, compensate for
SLE-related inflammation, or both.
FasL belongs to the tumor necrosis factor ligand family
and induces pro-apoptotic signals by binding to Fas [10].
Inhibition of Fas/FasL-mediated apoptosis by circulating
anti-FasL autoantibody may contribute to the immune
abnormalities and pathogenesis of SLE [42]. Over-
expression of membrane-bound Fas ligand (CD95L) ex-
acerbated autoimmune disease and renal pathology in
pristane-induced lupus [43], and administering anti-FasL
monoclonal antibody to an NZB/W F1 mouse model of
lupus prevented the development of lupus nephritis [44].
Our data did not show a significant correlation between
FasL mRNA expression and proportions of CD3+CD4+
Fas+ or CD3+CD4- Fas+ T cells. This discrepancy may re-
flect the fact that Fas is abundantly expressed in various
cell types.
The Tim-3 ligand, galectin-9, has attracted attention
for playing various roles in innate and adaptive immun-
ity [45]. The Tim-3/galectin-9 pathway regulates Th1
immunity, resulting in apoptosis of Th1 cells [21, 46].
Treating mouse models of experimental autoimmune
arthritis with galectin-9 ameliorated disease [17]. In con-
trast, our data showed no correlation between galectin-9
mRNA expression and proportions of CD3+CD4+Tim-3+
or CD3+CD4-Tim-3+ T cell subsets. This discrepancy
may reflect Tim-3-independent activity of galectin-9
under our experimental conditions. Galectin-9 can also
bind CD40 [46] and other receptors on T-cells [47], in-
cluding protein disulfide isomerase [48]. In addition,
galectin-9 suppresses Th17 cell development via a mech-
anism that is independent of Tim-3 but dependent on
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shown to ameliorate clinical severity of lupus-prone
MRL/lpr mice by inducing plasma cell apoptosis [49]. In
fact, one study found evidence that Tim-3 does not act
as a galectin-9 receptor [50]. Future studies should con-
firm that galectin-9 functions via Tim-3-dependent and-
independent mechanisms.
While our data on expression of Tim-3 and Fas are
consistent with the idea that T cells play an important
role in SLE by amplifying the autoimmune response
[51], we caution that we examined only CD3+CD4+ and
CD3+CD4- T cell subsets. Several other T cell subsets
have been implicated in SLE pathogenesis, including
Th17 cells [52, 53], Treg cells [54–56], T follicular helper
(TFH) cells [57, 58], and DN T cells [59, 60]. In addition,
we did not measure proportions of apoptotic cells or
whether Tim-3 is expressed at higher levels in those
cells than in non-apoptotic ones. Tim-3 and Fas are
known to be co-expressed in some T cell types, such as
Treg and Th17. Future studies should examine Tim-3
and Fas expression in these and other T subsets to gain
a clearer picture of their potential usefulness as a bio-
marker of SLE activity.Conclusions
In conclusion, our data indicate that patients with SLE
contain higher proportions of CD3+CD4+Tim-3+ and
CD3+CD4-Tim-3+ T cell subsets than HCs, and Tim-3
expression on CD3+CD4+ and CD3+CD4- T cells corre-
lates with SLE disease activity. Our data suggest that
Tim-3 and Fas can be co-expressed on the same T cell
subsets, and that the proportion of Tim+Fas+ cells is
higher in active SLE than stable SLE. This suggests a
close association between Tim-3 expression and T cell
apoptosis in patients with active SLE, and highlights the
need for future research to clarify how this association
contributes to disease pathogenesis.Competing interests
The authors declare that they have no competing interests.Authors’ contributions
LS and XW performed the experiments and wrote the manuscript; XW and
DL performed experiments. FD, HL and XY contributed to data analysis and
interpretation. XL and QS designed the experiments and revised the
manuscript. All authors read and approved the final manuscript.Acknowledgments
The authors thank Prof. Xiao-feng Zeng, Department of Rheumatology,
Peking Union Medical College Hospital, and Chinese Academy of Medical
Sciences. Prof. Xiao-feng Zeng is the Study Sponsor of the National 11th
Five-Year Technology Based Plan Topic on Lupus Diagnosis and Therapy
(2008BAl59802), of which the present project forms a part. This study was
also supported by the Natural Science Foundation of Shandong Province
(ZR2012HM038) and the Scientific Research Foundation for Returned
Overseas Chinese Scholars of the State Ministry of Education (2013693).Author details
1Department of Rheumatology, Qilu Hospital of Shandong University, 107
Wenhua Xi Road, Ji’nan 250012, China. 2The Key Laboratory of Cardiovascular
Remodeling and Function Research, Chinese Ministry of Education and
Chinese Ministry of Health, Qilu Hospital of Shandong University, Ji’nan
250012, China. 3Cryomedicine Laboratory, Qilu Hospital of Shandong
University, Ji’nan 250012, China.
Received: 8 October 2014 Accepted: 29 May 2015
References
1. Shah K, Lee WW, Lee SH, Kim SH, Kang SW, Craft J, et al. Dysregulated balance of
Th17 and Th1 cells in systemic lupus erythematosus. Arthritis Res Ther. 2010;12:R53.
2. Nagy G, Koncz A, Perl A. T- and B-cell abnormalities in systemic lupus
erythematosus. Crit Rev Immunol. 2005;25:123–40.
3. Song L, Qiu F, Fan Y, Ding F, Liu H, Shu Q, et al. Glucocorticoid regulates
interleukin-37 in systemic lupus erythematosus. J Clin Immunol. 2013;33:111–7.
4. Qiu F, Song L, Ding F, Liu H, Shu Q, Yang N, et al. Expression level of the
growth factor progranulin is related with development of systemic lupus
erythematosus. Diagn Pathol. 2013;8:88.
5. Munoz LE, van Bavel C, Franz S, Berden J, Herrmann M, van der Vlag J. Apoptosis
in the pathogenesis of systemic lupus erythematosus. Lupus. 2008;17:371–5.
6. Shao WH, Cohen PL. Disturbances of apoptotic cell clearance in systemic
lupus erythematosus. Arthritis Res Ther. 2011;13:202.
7. Xue C, Lan-Lan W, Bei C, Jie C, Wei-Hua F. Abnormal Fas/FasL and
caspase-3-mediated apoptotic signaling pathways of T lymphocyte subset
in patients with systemic lupus erythematosus. Cell Immunol. 2006;239:121–8.
8. Telegina E, Reshetnyak T, Moshnikova A, Proussakova O, Zhukova A,
Kuznetsova A, et al. A possible role of Fas-ligand-mediated “reverse
signaling” in pathogenesis of rheumatoid arthritis and systemic lupus ery-
thematosus. Immunol Lett. 2009;122:12–7.
9. Giovannetti A, Pierdominici M, Di Iorio A, Cianci R, Murdaca G, Puppo F
et al. Apoptosis in the homeostasis of the immune system and in human
immune mediated diseases. Curr Pharm Des. 2008;14:253–68.
10. Suda T, Takahashi T, Golstein P, Nagata S. Molecular cloning and expression
of the Fas ligand, a novel member of the tumor necrosis factor family. Cell.
1993;75:1169–78.
11. Bijl M, Horst G, Limburg PC, Kallenberg CG. Fas expression on peripheral
blood lymphocytes in systemic lupus erythematosus (SLE): relation to
lymphocyte activation and disease activity. Lupus. 2001;10:866–72.
12. Ho CY, Wong CK, Li EK, Lam WK. Effects of dexamethasone on the
expression of Fas molecules and apoptosis of lymphocytes in patients with
systemic lupus erythematosus. Immunol Invest. 2001;30:231–43.
13. Kovacs B, Liossis SN, Dennis GJ, Tsokos GC. Increased expression of
functional Fas-ligand in activated T cells from patients with systemic lupus
erythematosus. Autoimmunity. 1997;25:213–21.
14. McNally J, Yoo DH, Drappa J, Chu JL, Yagita H, Friedman SM et al. Fas
ligand expression and function in systemic lupus erythematosus. J Immunol.
1997;159:4628–36.
15. Sanchez-Fueyo A, Tian J, Picarella D, Domenig C, Zheng XX, Sabatos CA, et al.
Tim-3 inhibits T helper type 1-mediated auto- and alloimmune responses and
promotes immunological tolerance. Nat Immunol. 2003;4:1093–101.
16. Kearley J, McMillan SJ, Lloyd CM. Th2-driven, allergen-induced airway
inflammation is reduced after treatment with anti-Tim-3 antibody in vivo.
J Exp Med. 2007;204:1289–94.
17. Seki M, Oomizu S, Sakata KM, Sakata A, Arikawa T, Watanabe K, et al. Galectin-9
suppresses the generation of Th17, promotes the induction of regulatory T cells,
and regulates experimental autoimmune arthritis. Clin Immunol. 2008;127:78–88.
18. Li Z, Ju Z, Frieri M. The T-cell immunoglobulin and mucin domain (Tim)
gene family in asthma, allergy, and autoimmunity. Allergy Asthma Proc.
2013;34:e21–6.
19. Liu Y, Shu Q, Gao L, Hou N, Zhao D, Liu X, et al. Increased Tim-3 expression on
peripheral lymphocytes from patients with rheumatoid arthritis negatively
correlates with disease activity. Clin Immunol. 2010;137:288–95.
20. Monney L, Sabatos CA, Gaglia JL, Ryu A, Waldner H, Chernova T, et al.
Th1-specific cell surface protein Tim-3 regulates macrophage activation and
severity of an autoimmune disease. Nature. 2002;415:536–41.
21. Zhu C, Anderson AC, Schubart A, Xiong H, Imitola J, Khoury SJ, et al. The Tim-3
ligand galectin-9 negatively regulates T helper type 1 immunity. Nat Immunol.
2005;6:1245–52.
Song et al. Diagnostic Pathology  (2015) 10:71 Page 9 of 922. Kuchroo VK, Umetsu DT, DeKruyff RH, Freeman GJ. The TIM gene family:
emerging roles in immunity and disease. Nat Rev Immunol. 2003;3:454–62.
23. Kuchroo VK, Dardalhon V, Xiao S, Anderson AC. New roles for TIM family
members in immune regulation. Nat Rev Immunol. 2008;8:577–80.
24. NakayamaM,AkibaH,TakedaK,KojimaY,HashiguchiM,AzumaM,etal.Tim-3mediates
phagocytosis of apoptotic cells and cross-presentation. Blood. 2009;113:3821–30.
25. Wang Y, Meng J, Wang X, Liu S, Shu Q, Gao L, et al. Expression of human
TIM-1 and TIM-3 on lymphocytes from systemic lupus erythematosus
patients. Scand J Immunol. 2008;67:63–70.
26. Hochberg MC. Updating the American College of Rheumatology revised
criteria for the classification of systemic lupus erythematosus. Arthritis
Rheum. 1997;40:1725.
27. Gladman DD, Ibanez D, Urowitz MB. Systemic lupus erythematosus disease
activity index 2000. J Rheumatol. 2002;29:288–91.
28. Maeda N, Sekigawa I, Iida N, Matsumoto M, Hashimoto H, Hirose S.
Relationship between CD4+/CD8+ T cell ratio and T cell activation in
systemic lupus erythematosus. Scand J Rheumatol. 1999;28:166–70.
29. Shah D, Kiran R, Wanchu A, Bhatnagar A. Relationship between T
lymphocyte subsets and cortisol in systemic lupus erythematosus.
Kathmandu Univ Med J (KUMJ). 2009;7:213–9.
30. Funauchi M, Ikoma S, Enomoto H, Horiuchi A. Decreased Th1-like and
increased Th2-like cells in systemic lupus erythematosus. Scand J
Rheumatol. 1998;27:219–24.
31. Nambiar MP, Krishnan S, Tsokos GC. T-cell signaling abnormalities in human
systemic lupus erythematosus. Methods Mol Med. 2004;102:31–47.
32. Moulton VR, Tsokos GC. Abnormalities of T cell signaling in systemic lupus
erythematosus. Arthritis Res Ther. 2011;13:207.
33. Kammer GM, Perl A, Richardson BC, Tsokos GC. Abnormal T cell signal
transduction in systemic lupus erythematosus. Arthritis Rheum.
2002;46:1139–54.
34. Andrade F, Casciola-Rosen L, Rosen A. Apoptosis in systemic lupus
erythematosus. Clinical implications. Rheum Dis Clin North Am.
2000;26:215–27.
35. Green DR. Overview: apoptotic signaling pathways in the immune system.
Immunol Rev. 2003;193:5–9.
36. Courtney PA, Crockard AD, Williamson K, McConnell J, Kennedy RJ, Bell AL.
Lymphocyte apoptosis in systemic lupus erythematosus: relationships with
Fas expression, serum soluble Fas and disease activity. Lupus. 1999;8:508–13.
37. Li LH, Li WX, Wu O, Zhang GQ, Pan HF, Li XP, et al. Fas expression on
peripheral blood lymphocytes in systemic lupus erythematosus: relation to the
organ damage and lymphocytes apoptosis. Mol Biol Rep. 2009;36:2047–52.
38. Amasaki Y, Kobayashi S, Takeda T, Ogura N, Jodo S, Nakabayashi T, et al.
Up-regulated expression of Fas antigen (CD95) by peripheral naive and
memory T cell subsets in patients with systemic lupus erythematosus (SLE):
a possible mechanism for lymphopenia. Clin Exp Immunol. 1995;99:245–50.
39. Stranges PB, Watson J, Cooper CJ, Choisy-Rossi CM, Stonebraker AC, Beighton
RA, et al. Elimination of antigen-presenting cells and autoreactive T cells by Fas
contributes to prevention of autoimmunity. Immunity. 2007;26:629–41.
40. Hastings WD, Anderson DE, Kassam N, Koguchi K, Greenfield EA, Kent SC,
et al. TIM-3 is expressed on activated human CD4+ T cells and regulates
Th1 and Th17 cytokines. Eur J Immunol. 2009;39:2492–501.
41. Liberal R, Grant CR, Holder BS, Ma Y, Mieli-Vergani G, Vergani D, et al. The
impaired immune regulation of autoimmune hepatitis is linked to a
defective galectin-9/tim-3 pathway. Hepatology. 2012;56:677–86.
42. Suzuki N, Ichino M, Mihara S, Kaneko S, Sakane T. Inhibition of Fas/Fas
ligand-mediated apoptotic cell death of lymphocytes in vitro by circulating
anti-Fas ligand autoantibodies in patients with systemic lupus erythematosus.
Arthritis Rheum. 1998;41:344–53.
43. Bossaller L, RathinamVA, Bonegio R, Chiang PI, Busto P,Wespiser AR, et al.
Overexpression ofmembrane-bound fas ligand (CD95L) exacerbates autoimmune
disease and renal pathology in pristane-induced lupus. J Immunol. 2013;191:2104–14.
44. Nakajima A, Hirai H, Kayagaki N, Yoshino S, Hirose S, Yagita H, et al.
Treatment of lupus in NZB/W F1 mice with monoclonal antibody against
Fas ligand. J Autoimmun. 2000;14:151–7.
45. Wiersma VR, de Bruyn M, Helfrich W, Bremer E. Therapeutic potential of
Galectin-9 in human disease. Med Res Rev. 2013;33 Suppl 1:E102–26.
46. Vaitaitis GM, Wagner DH, Jr. Galectin-9 controls CD40 signaling through a
Tim-3 independent mechanism and redirects the cytokine profile of pathogenic
T cells in autoimmunity. PLoS One. 2012;7:e38708.
47. Su EW, Bi S, Kane LP. Galectin-9 regulates T helper cell function independently
of Tim-3. Glycobiology. 2011;21:1258–65.48. Bi S, Hong PW, Lee B, Baum LG. Galectin-9 binding to cell surface protein
disulfide isomerase regulates the redox environment to enhance T-cell
migration and HIV entry. Proc Natl Acad Sci U S A. 2011;108:10650–5.
49. Moritoki M, Kadowaki T, Niki T, Nakano D, Soma G, Mori H, et al. Galectin-9
ameliorates clinical severity of MRL/lpr lupus-prone mice by inducing plasma
cell apoptosis independently of Tim-3. PLoS One. 2013;8:e60807.
50. Leitner J, Rieger A, Pickl WF, Zlabinger G, Grabmeier-Pfistershammer K,
Steinberger P. TIM-3 does not act as a receptor for galectin-9. PLoS Pathog.
2013;9:e1003253.
51. Shlomchik MJ, Craft JE, Mamula MJ. From T to B and back again: positive
feedback in systemic autoimmune disease. Nat Rev Immunol. 2001;1:147–53.
52. Chen XQ, Yu YC, Deng HH, Sun JZ, Dai Z, Wu YW, et al. Plasma IL-17A is
increased in new-onset SLE patients and associated with disease activity.
J Clin Immunol. 2010;30:221–5.
53. Apostolidis SA, Crispin JC, Tsokos GC. IL-17-producing T cells in lupus nephritis.
Lupus. 2011;20:120–4.
54. Valencia X, Yarboro C, Illei G, Lipsky PE. Deficient CD4 + CD25high T
regulatory cell function in patients with active systemic lupus
erythematosus. J Immunol. 2007;178:2579–88.
55. Barath S, Aleksza M, Tarr T, Sipka S, Szegedi G, Kiss E. Measurement of
natural (CD4 + CD25high) and inducible (CD4 + IL-10+) regulatory T cells in
patients with systemic lupus erythematosus. Lupus. 2007;16:489–96.
56. Venigalla RK, Tretter T, Krienke S, Max R, Eckstein V, Blank N, et al. Reduced CD4
+, CD25- T cell sensitivity to the suppressive function of CD4+, CD25high,
CD127 -/low regulatory T cells in patients with active systemic lupus
erythematosus. Arthritis Rheum. 2008;58:2120–30.
57. Simpson N, Gatenby PA, Wilson A, Malik S, Fulcher DA, Tangye SG, et al.
Expansion of circulating T cells resembling follicular helper T cells is a fixed
phenotype that identifies a subset of severe systemic lupus erythematosus.
Arthritis Rheum. 2010;62:234–44.
58. Feng X, Wang D, Chen J, Lu L, Hua B, Li X, et al. Inhibition of aberrant
circulating Tfh cell proportions by corticosteroids in patients with systemic
lupus erythematosus. PLoS One. 2012;7:e51982.
59. Crispin JC, Oukka M, Bayliss G, Cohen RA, Van Beek CA, Stillman IE, et al.
Expanded double negative T cells in patients with systemic lupus
erythematosus produce IL-17 and infiltrate the kidneys. J Immunol.
2008;181:8761–6.
60. Crispin JC, Tsokos GC. Human TCR-alpha beta + CD4–CD8- T cells can derive
from CD8+ T cells and display an inflammatory effector phenotype. J Immunol.
2009;183:4675–81.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
